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One Sentence Summary: Mutant Pik3ca gives rise to venous malformations 
 
Abstract 
Venous malformations (VMs) are painful and deforming vascular lesions composed of dilated 
vascular channels, present from birth. Mutations in the TEK gene, encoding the tyrosine kinase 
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receptor TIE2, are found in approximately half of sporadic (non-familial) VMs, and the causes of 
the remaining cases are unknown. Sclerotherapy, widely accepted as first-line treatment, is not fully 
efficient, and targeted therapy for this disease remains underexplored. In this study, we have 
generated a mouse model that faithfully mirrors human VM through mosaic expression of 
Pik3caH1047R, a constitutively active mutant of the p110α isoform of PI 3-kinase (PI3K), in the 
embryonic mesoderm. Endothelial expression of Pik3caH1047R resulted in endothelial cell (EC) 
hyperproliferation, reduction in pericyte coverage of blood vessels, and decreased expression of 
arteriovenous specification markers. PI3K pathway inhibition with rapamycin normalized 
endothelial cell hyperproliferation and pericyte coverage in postnatal retinas and stimulated VM 
regression in vivo. In line with the mouse data, we also report the presence of activating PIK3CA 
mutations in human VMs, mutually exclusive with TEK mutations. Our data demonstrate a causal 
relationship between activating Pik3ca mutations and the genesis of VMs, provide a genetic model 
that faithfully mirrors the normal etiology and development of this human disease, and establish the 
basis for the use of PI3K-targeted therapies in VMs.  
 
Introduction 
Enzymes in the PI3K family signal downstream of a variety of cell surface receptors to regulate 
multiple cellular functions, including growth and proliferation (1). The p110α isoform of 
phosphoinositide 3-kinase (PI3K), encoded by the PIK3CA (OMIM 171834) gene, is frequently 
activated through mutation in cancer (2). Similar activating mutations in PIK3CA have recently 
been linked to non-cancerous disease conditions, such as a spectrum of regional overgrowth 
disorders (3-6) [which have now been designated under the umbrella term PIK3CA-Related 
Overgrowth Spectrum (PROS) disease (7)] and isolated (not associated with overgrowth) lymphatic 
malformations (LMs) (8). In these conditions, the PIK3CA mutations are present from birth and 
occur in a mosaic pattern, mainly in tissues of mesodermal origin. This contrasts with somatic 
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PIK3CA mutations in cancer, which are almost exclusively present in epithelial tissues. The 
PIK3CA mutations present in PROS and LMs are similar to those found in solid tumors, with the 
H1047R mutation in the catalytic domain being the most prevalent (8,9). In this study, we report 
the presence of somatic activating PIK3CA mutations in another human disease condition of 
mesodermal origin, namely isolated VMs. In addition, we created a genetically-modified mouse 
model that displays mutant Pik3ca-driven congenital vascular malformations with features 
pathognomonic for human VMs. 
VMs are the most common vascular malformations, with an overall incidence of 1/5000 (10). 
VMs are usually congenital lesions that consist of dilated venous channels with scarce mural cell 
coverage. These VMs can be of different sizes and be present in any tissue, such as subcutaneous 
tissue or internal organs. VMs are painful and disfiguring, with many causing bleeding and 
obstruction of organs, and in some cases localized intravascular coagulopathy and pulmonary 
embolism (11,12). Treatment of VMs mainly consists of alleviation of symptoms with compression 
garments when possible, and curative treatment is seldom achievable. At present, sclerotherapy is 
the mainstay therapy to diminish the volume of VMs, but it causes a variety of side effects and is 
not fully effective (12).  
Mutations in the TEK gene, which codes for the endothelial tyrosine kinase receptor TIE2, are 
known to cause about half of sporadic VMs (13); the cause of the other half remains unknown. 
Here, in a cohort of patients diagnosed with sporadic VMs, without any associated overgrowth, we 
found PIK3CA-activating mutations in a mutually exclusive manner to previously identified 
mutations in TEK (14). This was corroborated by a study in the accompanying paper by Castel et 
al. (15), in which PIK3CA mutations were found in 25% of the VMs analysed, again in a mutually 
exclusive manner to TEK mutations. The finding that activating mutations in PIK3CA play a key 
role in the pathogenesis of VMs provides guidance for refined diagnosis for this disease and a 
possible targeted therapeutic intervention with PI3K pathway inhibitors. 
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Results 
Mosaic Pik3caH1047R expression in embryonic mesoderm causes VMs in mice 
In this study, we set out to investigate the effects of Pik3ca mutation in mesodermal tissue in mice. 
Given that all known disease conditions of mesodermal origin currently associated with PIK3CA 
mutations are congenital or early childhood onset, we induced expression of mutant Pik3ca in the 
embryonic mesoderm. To more precisely model the human disease context, mutant Pik3ca 
expression was induced in a mosaic fashion, in the heterozygous state and from its endogenous 
promoter (16). We reasoned that such tissue-restricted mosaic induction could also avoid the 
detrimental effects of ubiquitous expression of mutant Pik3ca during embryonic mouse 
development (17). The mutant used for these experiments was Pik3caH1047R, which encodes the 
H1047R hot-spot mutation found in cancer (2), LMs (8) and PROS (9). 
 For these studies, we generated a mouse line (referred to as T-CreERT2) by introducing a 
transgene (Fig. S1A) that drives the expression of a 4-hydroxytamoxifen (4-OHT)-inducible Cre 
recombinase under the control of the previously characterized promoter of the T gene (18). The T 
gene encodes the Brachyury transcription factor that is transiently expressed in the nascent 
embryonic mesoderm (19). To evaluate Cre activity, we crossed T-CreERT2 mice with Rosa26-lacZ 
reporter mice (20) that ubiquitously express the floxed lacZ gene expression cassette from the 
Rosa26 locus (Fig. S1B), and stained for lacZ expression after treatment of mice with 4-OHT. We 
administered 4-OHT to pregnant females between embryonic day (E) 7.5 and 10.5. In line with the 
known temporal expression of the T gene (19), induction of Cre produced a widespread lacZ 
expression in the mesoderm, which was highest at E7.5 (Fig. S1C). Cre activity at E7.5 was 
dependent on the 4-OHT dose and was present in a mosaic pattern, except at the higher doses tested 
(Fig. S1D). 
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We next crossed T-CreERT2 mice to mice that are heterozygous for a Cre-inducible knock-in 
allele of Pik3caH1047R (16), followed by mosaic Pik3caH1047R induction at E7.5 with different doses 
of 4-OHT (Fig. 1A). Several of these mice [hereafter referred to as MosMes-Pik3caH1047R (Mosaic 
Mesodermal-Pik3caH1047R) mice] but not T-CreERT2;Pik3caWT (hereafter referred to as WT) 
littermate mice, were born with subcutaneous vascular malformations in different body sites (Fig. 
1B). No apparent overgrowth was observed in other tissues, nor alterations in body weight, organ 
size or tissue histology (tested up to 6 months of age), compared to WT littermate mice that had 
also been treated with 4-OHT (Fig. S2; Table S1). This phenotype was not fully penetrant at lower 
4-OHT doses, but increased in a dose-dependent manner (Table S2). The lower doses of 4-OHT 
tested gave rise to localized vascular lesions, whereas the higher doses, possibly because of the 
higher probability of targeting multiple EC progenitors, induced multifocal, diffuse, and more 
severe malformations (Fig. 1B). High 4-OHT doses also resulted in a lower than expected 
Mendelian distribution of mutant mice (Table S3), with some of the mutant embryos displaying 
vascular developmental defects (Fig. S3). Our observations on the lethality and vascular defects in 
MosMes-Pik3caH1047R embryos are similar to the previously reported phenotypes of ubiquitous or 
EC-specific expression of Pik3caH1047R in the developing embryo (17). 
Computed Tomography Angiography (CT-A) analysis of adult MosMes-Pik3caH1047R mice 
confirmed the presence of subcutaneous vascular malformations and revealed additional internal 
vascular malformations in the mesentery and urogenital area (Fig. 1C,D). Some of these mice 
displayed rectal bleeding and phlebectasias of the portal vein and inferior vena cava (Fig. 1C), 
similar to those observed in patients with venous vascular malformations (reviewed in (21)). 
Additional scanning of blood flow in the vascular malformation by power Doppler ultrasound 
indicated that the contribution of flow was primarily venous in origin (slow flow) (Fig. S4). This 
was corroborated by histological analysis which showed that the vascular lesions in MosMes-
Pik3caH1047R mice were poorly circumscribed, non-encapsulated lesions composed of blood-filled, 
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predominantly thin-walled, irregular and variably sized blood vessels interposed between normal 
tissues (Fig. 1D). Some blood vessels contained organising fibrin thrombi, with focal interstitial 
hemorrhage present. Immunostaining of these vascular lesions for lymphatic markers (LYVE-1, 
PROX-1) revealed the presence of malformed lymphatic vessels (Fig. S5), however, the lymphatic 
component was much less prominent than the aberrant blood vessels. This is similar with what is 
seen in humans, where purely vascular malformations are rare and usually contain a mixture of 
vessel types, with some types being pathologically prominent such as the blood vessels in the case 
of VMs (22).  
Altogether, these observations point to a diagnosis of VMs in MosMes-Pik3caH1047R mice, with 
a pathology and disease burden remarkably similar to those observed in humans with VMs.  
 
PIK3CA is mutated in human VMs 
Having identified the causative role of activating Pik3ca mutation in VMs in mice, we explored the 
presence of PIK3CA mutations in human VMs. We analysed PIK3CA and TEK genes by deep 
sequencing (mean coverage of 2000x) in human sporadic VMs that had no associated overgrowth 
or other predominant vascular malformation component. Among the VMs sequenced, 3/13 (23%) 
were mutant for PIK3CA (Fig. 2) and 6/13 (46%) for TEK, with an allelic frequency of 4-13% 
(Table 1). Interestingly, mutations in PIK3CA and TEK were mutually exclusive. The observed 
PIK3CA mutations are hot-spot mutations in cancer (2), PROS (9) and LMs (8), with the observed 
TEK mutations having previously been described for VMs (23). In line with our observations, 
Castel et al. in the accompanying manuscript (15) found that PIK3CA was mutated in 25% of VM 
cases. Taken together, these findings indicate that PIK3CA mutation status could be a relevant 
diagnostic marker for human VMs and corroborate a causal role of PIK3CA mutation in VM 
generation. 
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Endothelial activation of Pik3ca promotes hyperproliferation in ECs and impairs pericyte 
coverage 
ECs, being the main cell type in the microvasculature, are thought to be important in VM 
development. Given the key role for Pik3ca in EC biology (24-28), we decided to selectively test 
the impact of Pik3caH1047R expression in ECs using postnatal retina as a model of angiogenesis. To 
this end, we generated EC-Pik3caH1047R mice by crossing conditional heterozygous Pik3caWT/H1047R 
mice onto Pdgfb-iCreER mice that express 4-OHT-inducible Cre specifically in ECs (29) (Fig. S6). 
4-OHT was administered to EC-Pik3caH1047R pups on postnatal day 1 (P1), and retinal angiogenesis 
was analyzed five days later (Fig. 3A). Staining of P6 retinas with isolectin-B4 (IB4, which binds 
specifically to the EC plasma membrane) revealed that endothelial expression of Pik3caH1047R 
resulted in dramatic hyperplasia, with individual vessels no longer being discernible, correlating 
with increased proliferation and numbers of ECs (Fig. 3B, C). This increase in EC number was 
confirmed by the higher levels VE-Cadherin in EC-Pik3caH1047R retinas Fig. S7). Radial expansion 
of the vascular bed was also decreased upon endothelial expression of Pik3caH1047R, possibly due to 
EC hyperplasia (Fig. 3D, E), whereas sprouting angiogenesis, as measured by number and length of 
sprouts, was not affected (Fig. 3D, F). In addition, at P9, when mouse retinas have started vascular 
remodeling, EC-Pik3caH1047R-driven hyperplasia persisted, and there was no difference in apoptosis 
(as assessed by expression of cleaved caspase-3) between EC-Pik3caH1047R and Pik3caWT retinas 
(Fig. S8), indicating that there was no compensation of Pik3caH1047R-driven hyperplasia by 
enhanced apoptosis during the remodeling process. 
A distinctive feature of human VMs is the low number, or even absence, of mural cells (30). 
Proper homeostasis of vessels requires a tight interplay between ECs and their supporting mural 
cells, which are perivascular cells of two types, vascular smooth muscle cells (vSMCs) and 
pericytes. Both cell types are differently distributed over the vasculature, with vSMCs typically 
present in large vessels and pericytes mainly localized in the microvasculature (31). In EC-
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Pik3caH1047R retinas at P6, pericytes (NG2-positive cells) were conspicuously absent from the 
vascular front and very sparse in the plexus, where they were poorly associated with the vessels, in 
contrast with Pik3caWT retinas that showed a typical attachment of pericytes to the EC surface with 
multiple extensions (Fig. 3G, H). Defective mural cell coverage was also observed in the VMs from 
MosMes-Pik3caH1047R mice (Fig. 1D).  
PDGF-B, which is produced by ECs, is the major attractant for pericytes (32) and is present in 
lower amounts in human TEK-mutant VMs (33). The FOXO1 transcription factor, which is 
negatively regulated by PI3K activity, stimulates PDGF-B expression. In line with this, analysis of 
total mRNA isolated from retinas and lungs (a tissue highly enriched in ECs) from postnatal P6 
mice showed a decrease in Pdgfb expression in EC-Pik3caH1047R mice compared to Pik3caWT mice 
(Fig. 3I, S9A). The pericyte phenotype observed in EC-Pik3caH1047R retinas is reminiscent of that 
observed in the so-called Pdgfb-retention motif knock-out mice, in which PDGF-B produced by the 
ECs is not retained at the cell surface (34). 
Throughout development and in adult life, arteriovenous specification in ECs is associated with 
selective expression of specific genes (35). The mRNA expression of three proteins known to be 
key in this process, namely COUP-TFII (encoded by the Nr2f2 gene) and Eph-B4 (encoded by the 
Ephb4 gene), which are expressed in venous ECs, and Ephrin-B2 (encoded by the Efnb2 gene), 
which is selectively expressed in arterial ECs, was reduced in EC-Pik3caH1047R postnatal retinas and 
lungs compared to those in Pik3caWT mice (Fig. 3J, S9B). This finding indicates that endothelial 
expression of Pik3caH1047R compromises arteriovenous identity of ECs.  
Taken together, our findings show that Pik3caH1047R expression in ECs results in EC 
hyperproliferation, defective pericyte coverage, and loss of arteriovenous identity.  
 
Rapamycin reduces Pik3caH1047R EC hyperproliferation and prevents loss of pericyte coverage 
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At the moment, there are no targeted therapies for VMs. Rapamycin and its analogs interfere with 
signaling downstream of PI3K by inhibition of mTOR (36) and are approved for compassionate use 
in human therapy of vascular anomalies (37-43). To test the effect of rapamycin on Pik3caH1047R 
ECs in vivo, we treated EC-Pik3caH1047R pups with rapamycin first at P1 (administered together 
with 4-OHT) followed by a second injection at P5 (8 h before analysis of retinal angiogenesis; Fig. 
4A). Drug treatment prevented retinal vascular hyperplasia, reduced the number of ECs and 
proliferation (Fig. 4B, C), and normalized pericyte coverage in both the vascular front and plexus of 
EC-Pik3caH1047R retinas (Fig. 4D). Rapamycin also decreased vessel area and number of ECs in 
Pik3caWT retinas, with a borderline reduction in EC proliferation (Fig. 4B, C), in line with its 
previously documented anti-angiogenic effects (44). 
 
Rapamycin induces regression of Pik3caH1047R-driven VMs in vivo 
  To take these observations closer to the disease context, adult MosMes-Pik3caH1047R mice with 
VMs were treated with rapamycin (Table 2). The rapamycin dose chosen for this study (4 mg/kg 
every other day) was based on previous studies using long-term rapamycin treatment (45,46). In 
WT mice, this dose was found to have no detectable impact on overall health, weight, or behavior 
(Table 2). Due to different degrees of severity of the VMs, only mice that were deemed to be 
sufficiently fit to tolerate the treatment were included. The mice recruited to this therapeutic 
experiment had subcutaneous VMs that were heterogeneous in size and location, in some cases 
accompanied with phlebectasias of main internal veins (inferior vena cava, portal vein). Two weeks 
of rapamycin treatment resulted in a ~25% reduction in the volume of the VMs, as assessed by CT-
A (Fig. 5, S10), with a cessation of bleeding from the VM or anus shortly after the start of the 
treatment with rapamycin. Continued treatment showed progressive regression of the VMs (Fig. 5, 
Fig. S10). Overall, these observations are in line with data from a study on VM patients with a wide 
range of lesions, in which a heterogeneous response to rapamycin treatment was observed, with 
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reduction in VM volume between 10-20%, resulting in symptom improvement and clinical benefit 
(43). 
Overall, our data suggest that PI3K pathway intervention might be an effective therapeutic 
option for human PIK3CA-driven VMs. 
 
Discussion 
Here we identify the presence of activating PIK3CA mutations in human VMs and report a genetic 
mouse model for this disease. We demonstrate that somatic, mosaic expression of an activating 
mutation (H1047R) in Pik3ca in the embryonic mesoderm of mice can induce and maintain VMs. 
Previous mouse models of VM have used transgenic expression of a murine viral oncogene (47) or 
xenotransplantation into nude mice of either human vascular endothelial cells (HUVECs) 
transduced with mutant TEK (43) or the MS1 immortalized endothelial cell line expressing mutant 
AKT1 (48). Xenograft models do not take into account the developmental origin and natural 
progression of the human disease nor the complex admixture of vessel and stromal cells in human 
VM lesions. They also show full regression upon rapamycin treatment, which was not observed in 
our mouse models, in which regression was very variable after long-term treatment, in line with 
observations in human VM patients (43). The xenograft models may therefore be a less predictive 
model for the human disease. Yet, our mosaic mesodermal VM mouse model shows some 
limitations for use in standardized uniform cohort therapeutic experiments, namely some degree of 
embryo lethality, a variable penetrance of the VM phenotype, and a large heterogeneity of VMs in 
terms of size, localization, and expansion. However, these limitations of our mouse model 
adequately reflect the characteristics of this human disease, with every patient showing a distinct 
disease pattern, progression, and response to therapy, most likely resulting from the spatially and 
temporally distinct and mosaic acquisition of the mutation causing the disease. Of note, activation 
of PI3K signaling in adult mice, either by ubiquitous expression of mutant Pik3ca from its 
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endogenous promoter (49) or EC-specific expression of transgenic activated Akt1 (50) increases 
blood vessel size without inducing VMs. This underscores the concept that VMs arise as a result of 
genetic errors during embryonic development. 
Mechanistically, our data suggest that VMs are likely to develop as a result of Pik3caH1047R-
induced enhancement of EC proliferation during embryonic vasculogenesis. Indeed, EC 
hyperproliferation during vasculogenesis has previously been shown to give rise to vessel 
hyperfusion, and to result in dilated, dysfunctional vessels, similar to those found in VMs (51,52). 
Another typical feature of VMs is poor mural cell coverage (30). We also show that Pik3caH1047R 
expression in ECs inhibits pericyte attachment, likely because of the decreased expression of 
PDGF-B, which is necessary for pericyte coverage (53). This might therefore also contribute to the 
genesis of VMs upon Pik3ca mutation. Lastly, Pik3caH1047R might also contribute to the formation 
of VMs by preventing arteriovenous differentiation, as seen by decreased expression of 
arteriovenous differentiation markers (54). It is therefore tempting to speculate that VMs could be 
the result of hyperproliferation of ECs and lack of maturation of primitive capillary beds as a 
consequence of PI3K pathway overactivation. 
At present, it is not clear why widespread mosaic induction of Pik3caH1047R in the mouse 
mesoderm gives rise to malformations solely in the vasculature and does not induce obvious 
overgrowth or malformation in other tissue compartments. This might be due to the chosen strategy 
(timing and tissue location) of Pik3caH1047R gene induction. However, Castel et al. in the 
accompanying manuscript (15) have made similar observations in their models. One explanation 
could be the previously reported exceptional sensitivity of ECs to PI3K pathway deregulation (24-
28). 
Human genetic data presented here and in the accompanying manuscript (15) reveal the 
presence of PIK3CA mutations in VMs, mutually exclusive with mutations in the TEK gene that 
were discovered over 20 years ago (30). Our studies thus uncover and document the potential for a 
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new targeted therapy in human VMs, and the potential for repurposing of p110α inhibitors currently 
being developed for cancer treatment. An important consideration is how diagnosis of TEK and 
PIK3CA mutations in VMs can influence the treatment of this disease using targeted agents. The 
wild-type TIE2 receptor tyrosine kinase is known to signal through both the PI3K and MAPK 
signaling pathways in ECs (55,56). Both pathways have been implicated in signaling downstream 
of mutant TIE2 in ECs, with their relative contribution to biological outputs not being clear at 
present (14,33,43). TEK-mutant cells surprisingly do not respond to TIE2 kinase inhibitors (43), 
possibly because mutant TIE2 kinase is not very responsive to drugs that were developed against 
the wild-type TIE2. TEK-mutant cells show chronic activation of the PI3K and MAPK pathways 
and respond very well to inhibition of each of these pathways (14). Our studies identify a 
subpopulation of patients with PIK3CA-mutant VMs, which will most likely be non-responsive to 
TIE2 or MAPK inhibitors. However, like the TEK-mutant VMs (43), PIK3CA-mutant VMs are 
expected to respond to PI3K inhibitors or rapamycin. It is also likely that TEK-mutant VMs will 
benefit from treatment with PI3K inhibitors in combination with MAPK inhibitors.  
In conclusion, our findings in mice allowed us to discover the presence of PIK3CA mutations in 
a human disease. VMs join the growing list of diseases where the presence of activating PIK3CA 
mutations, commonly associated with cancer, results in tissue malformation without causing 
malignancy (8,9). Our finding that mutation in PIK3CA plays a key role in the pathogenesis and 
maintenance of VMs provides guidance for improved diagnosis for this disease and a possible 
targeted therapeutic avenue using PI3K pathway inhibitors. 
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Materials and Methods 
Study design 
This study was designed to test the effect of Pik3caH1047R expression in the embryonic mesoderm of 
mice. We obtained sufficient data on mice to determine that this results in VMs. To translate these 
findings to the human context, we tested for PIK3CA mutation in human VMs and found that this 
gene is mutated in this disease. For this, well-characterized patients with confirmed VMs and 
without any associated overgrowth or malformation were recruited at Great Ormond Street 
Hospital, London, UK. All patients provided informed consent. In addition, to better understand the 
mechanisms underlying the role of Pik3caH1047R in ECs, we performed mouse retinal angiogenesis 
studies as a vascular biology read-out. For these experiments, we performed a power analysis on 
preliminary data, suggesting that a minimal cohort size of n=4-6 is necessary to observe a 
significant difference with 80% power, depending on the type of experiment. The sample size for 
each experiment is indicated in the corresponding figure legend. Given that n was <10, non-
parametric tests were applied. All mechanistic studies were performed without randomization or 
blinding. Exclusion criteria were only applied to data shown in Fig. 4 (rapamycin treatment of 
mouse harboring VMs): only mice that were deemed to be sufficiently fit to tolerate the treatment 
were included in the experiment. This is in line with UK Home Office regulations. 
 
Subjects 
This study was approved by the UK National Research Ethics Committee. Written informed 
consent was obtained from all participants or their parents. Tissues from individuals diagnosed as 
having sporadic VMs, not associated with other syndromes, were investigated. Genomic DNA was 
extracted from lesions using standard procedures. 
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Next generation sequencing with preceding target enrichment 
Sequencing of TEK and PIK3CA was performed using Next Generation Sequencing with preceding 
target enrichment. All equipment and materials were purchased from Life Technologies, Thermo-
Fisher Scientific. In brief, DNA was quantified using Qubit, and libraries were prepared using the 
Ion AmpliSeq Library 96 Kit 2.0 with 10 ng of genomic DNA in each reaction. This involved an 
initial PCR reaction to amplify genomic targets using a custom-designed primer pool which 
provides coverage of all coding regions of PIK3CA and TEK (primer sequences available upon 
request). Samples were then partially digested before ligation of barcode adaptors and emulsion 
PCR. Enrichment steps were carried out using the Ion OneTouch 200 Template Kit v2, the 
amplicon libraries were sequenced on an Ion Torrent Personal Genome Machine system using 318 
chips, and bar-coding was applied with an Ion Xpress Barcode Adapters 1–16 Kit. Ion Reporter 
software was used to analyze data, or alternatively Bam files were uploaded and viewed in the 
Integrative Genomics Viewer, Broad Institute (http://www.broadinstitute.org/igv/). The mean depth 
of coverage for sequencing was 2000X. 
 
Reagents 
Primary antibodies to the following proteins were used: Erg (ab92513; Abcam), NG2 (AB5320; 
Merck Millipore), endomucin (sc-65495; Santa Cruz Biotechnology), LYVE-1 (AF2125; R&D 
Systems), PROX-1 (PRB-238C; Covance), and Cleaved caspase-3 (9664S; Cell Signalling 
Technology). Secondary antibodies conjugated to Cy3, Cy5, or AlexaFluor 647 were from Jackson 
ImmunoResearch Laboratories. For immunohistochemistry (IHC), biotinylated antibodies were 
from Vector Laboratories. Isolectin GS-IB4 conjugated to AlexaFluor 488 (I21411) or AlexaFluor 
568 (I21412) (further referred to as IB4) was from Life Technologies. Immu-Mount mounting 
medium was from Thermo Scientific. AuroVist 15 nm gold nanoparticles were from Nanoprobes 
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Inc. Rapamycin used for therapeutic studies was obtained from Merck Millipore. All chemicals, 
unless otherwise stated, were from Sigma-Aldrich. 
 
Mice 
Mice were housed in individually-ventilated cages and cared for according to UK Home Office 
guidelines and legislation, with procedures accepted by the Ethics Committees of University 
College London and Queen Mary University of London. All mice used were backcrossed on a 
C57BL/6 background for more than 12 generations. Pik3caWT/H1047R mice harbor a germline Pik3ca 
allele with a conditional H1047R mutation (16). In these mice, LoxP sites flank exon 20 of Pik3ca, 
which, upon Cre recombination, is replaced by a downstream copy of exon 20 containing a CAT to 
AGG change in codon 1047. Pdgfb-iCreER mice (29) express an inducible iCreER recombinase 
from the endogenous Pdgfb locus. 
 
Generation of the T-CreERT2 mouse line  
The pTcreERT2 vector (Fig. S1), comprising the T regulatory sequence from -1050 bp to +140 bp 
(18) was inserted upstream of a CreERT2 sequence. To eliminate uninduced background activity of 
Cre in the absence of 4-OHT, the nls sequence at the 5’ of CreERT2 was removed. This plasmid was 
FspI-linearized and electroporated into E14TG2a ES cells as described previously (57). After 10 
days of selection with hygromycin (140 µg/ml), resistant clones were isolated, expanded, and 
screened by Southern blot to verify integration of the transgene and to identify ES clones with 
single and multiple insertions of the transgene. Clones were tested in parallel by in situ 
hybridisation for Cre expression in differentiating ES cells. Four clones (three with a single 
integration and one with two integrations) that showed the characteristic spatial pattern of T 
expression in differentiating ES cell monolayers (58) were selected for further analysis. Absence of 
uninduced background recombination and 4-OHT-induced Cre recombination in these four clones 
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were tested in vitro by transient transfection of a Cre-conditional Egfp transgene (pPHCAG-C2-
egfp, a gift from Austin G. Smith, Wellcome Trust, Medical Research Council Cambridge Stem 
Cell Institute, UK). Clones with single T-CreERT2 integration showed efficient recombination upon 
treatment with 0.2 M or 1 M of 4-OHT, with virtually no background of uninduced 
recombination. These clones were injected into C57BL/6 host blastocysts and chimeric male 
offspring mated to C57BL/6 females. F1 heterozygotes were identified by coat color and PCR 
amplification of the Cre sequence. Offspring were backcrossed for >5 generations to C57BL/6 mice 
before generating a homozygote T-CreERT2 line by intercrossing. After further characterization by 
crosses with Rosa26-lacZ reporter mice (20), one T-CreERT2 mouse line (number 53) was 
maintained and established in the homozygote state. 
 
Mesoderm- and EC-specific Pik3caH1047R expression in mice 
Mesoderm-specific mosaic expression of Pik3caH1047R (MosMes-Pik3caH1047R mice) was achieved 
by crossing Pik3caWT/H1047R mice with T-CreERT2 mice. To induce mosaic Cre activation, pregnant 
females were given varying doses of 4-OHT (12.5 to 250 µg, from a stock solution of 10 mg/ml, 
diluted in 1:1 absolute ethanol-Kolliphor EL), with 200 µl of PBS added for intraperitoneal 
injection at E7.5 (E0.5 relates to the presence of a vaginal plug indicating that the mating occurred 
the night before). Progesterone (dissolved in Kolliphor EL) was co-administered at half the total 
dose of 4-OHT, to avoid undesirable estrogen agonist effects of 4-OHT, which can result in late 
fetal abortions in pregnant mice. Postnatal EC-specific expression of Pik3caH1047R was achieved by 
crossing Pik3caWT/H1047R with Pdgfb-iCreER mice. To induce Cre activation, newborn pups (P1) 
were injected intragastrically with 5 μg 4-OHT (dissolved in absolute ethanol). 
 
Histology and IHC 
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Mouse tissues and VMs were fixed in 4% PFA and embedded in paraffin. 5 μm sections were 
stained with hematoxylin-eosin using standard histology procedures. Immunostaining was 
performed using the automated Discovery XT slide staining system (Ventana Medical Systems) at 
the Molecular Cytology Core in Memorial Sloan Kettering Cancer Center (New York, USA). 
Briefly, tissue sections were deparaffinised with EZPrep buffer, and antigen retrieval was 
performed with CC1 buffer (Ventana Medical Systems). Sections were blocked for 30 min. with 
Background Buster solution (Innovex) (for PROX-1 antibody) or 10% rabbit serum (for LYVE-1 
antibody) followed by endogenous avidin/biotin blocking for 8 min. Then, sections were incubated 
with specific antibodies for 3 h, followed by incubation with biotinylated secondary antibodies. All 
slides were scanned using Zeiss Mirax Midi digital slide scanner. 
 
Whole-mount embryo X-gal staining 
Freshly isolated E12.5 embryos were fixed in 4% paraformaldehyde on ice for 30 min, washed (3 x 
10 min) in PBT (PBS with 0.1% Tween), and stained for 48 h at 30ºC in X-gal staining solution (4 
mM potassium ferricyanide, 4 mM potassium ferrocyanide, 2 mM MgCl2, and 1 mg/ml X-gal in 
PBT). After staining, embryos were washed (3 x 10 min) in PBS, post-fixed in 4% 
paraformaldehyde for ≥ 1 h and mounted. 
 
Whole-mount embryo immunofluorescence 
Freshly isolated E9.5 embryos were fixed in 4% paraformaldehyde overnight at 4°C. After washing 
in PBT, embryos were dehydrated in increasing concentrations of methanol (50%, 80% 
methanol/PBT, 100% methanol), rehydrated in decreasing concentrations of methanol, then washed 
for 30 min in Pblec buffer (0.2 mM CaCl2, 0.2 mM MgCl2, 0.2 mM MnCl2, and 2% Triton X-100 
in PBS) and incubated overnight at 4°C with antibody to endomucin, diluted 1:20 in Pblec. After 
five washes in PBT, embryos were incubated with Cy5-labeled secondary antibody diluted 1:100 in 
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PBS, 0.5% BSA, 0.25% Tween-20. Finally, embryos were washed three times in PBS, post-fixed 
for 1 min in 4% paraformaldehyde, and mounted. 
 
Mouse imaging by CT-A 
Mice were anesthetized with an isoflurane/O2 mix and tail vein cannulated for the delivery of 
approximately 0.1 ml of gold nanoparticles per 25 g of mouse weight. Animal temperature was 
maintained at 37C, with monitoring and maintenance of respiration at 60 breaths/min. Mice were 
placed in the supine position 4 h after injection of gold nanoparticles and whole body CT scans 
were acquired using a nanoScanPET/CT scanner (Mediso) with a 50 kVP X-ray source and 300 ms 
exposure time in 720 projections with an acquisition time of 15 min. CT images were reconstructed 
in voxel size 68 x 68 x 68 m using Nucline (Mediso) software. Image analysis and 3D 
visualization was performed using VivoQuant (inviCRO version 1.23patch3) software. 
 
Mouse imaging by Doppler ultrasound 
A Vevo 2100 imaging station (VisualSonics Inc.) was used for ultrasound imaging. A VisualSonics 
MS-550D (central frequency 40 MHz, axial resolution 40 µm, lateral resolution 90 m, image 
depth 15 mm, image width 14 mm) was used for data acquisition. Mice were anesthetized with an 
isoflurane/O2 mix and placed on a heated imaging stage maintained at 37C. The body temperature, 
heart rate, and respiratory rate were closely monitored throughout each imaging session. Abdominal 
hair was removed using a depilatory cream (Veet, Reckitt Benckiser) and rinsed with warm water. 
Pre-warmed ultrasound gel (UltrasoundGel.co.uk) was then placed on the abdomen. Flow velocity 
waveforms of vascular lesions were obtained by locating with color Doppler, power Doppler, and 
then placing the pulsed wave Doppler sample gate within the vessels and at the appropriate angle 
relative to flow direction. 2D-guided M-mode images were obtained to measure maximum vessel 
diameter. Images were analyzed with the VisualSonics Vevo 2100 software package.  
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Retinal angiogenesis 
Newborn pups (P1) were injected intragastrically with 5 μg 4-OHT dissolved in absolute ethanol at 
5 mg/ml. P6 eyes were harvested and fixed for 1 h in 4% PFA at 4°C and washed in PBS. Retinas 
were dissected, stained with IB4 and flat-mounted, or processed for immunostaining (59). For 
immunostaining, fixed retinas were blocked and permeabilized with blocking buffer (1% BSA, 
0.3% Triton X-100 in PBS) for 4 h at 4°C, then incubated overnight at 4°C with the corresponding 
primary antibodies [anti-Erg (1/300), anti-NG2 (1/200), anti-Cleaved-caspase 3 (1/50)] in blocking 
buffer and washed in PBT (3 x 10 min). After 30 min incubation in Pblec, retinas were incubated 
for 2 h with the corresponding labelled secondary antibody and IB4 in Pblec, washed with PBT (3 x 
10 min), post-fixed with 4% paraformaldehyde for 1 min, and flat-mounted. 
 
In vivo EC proliferation 
Pups were injected intraperitoneally with 50 μl of EdU (diluted to 2 mM in 1:1 DMSO-PBS) 2 h 
before harvesting of the eyes. EdU was detected with Click IT EdU Alexa Fluor-647 (Life 
Technologies) according to the manufacturer’s instructions. Retinas were then labelled with the 
corresponding antibodies and IB4 as described above. Retinas were imaged with a Zeiss LSM 700 
confocal microscope. EdU-positive nuclei were counted as proliferating ECs in a 100 µm2 region at 
the angiogenic front or plexus using the ImageJ software. 
 
RNA extraction and quantitative PCR 
Total RNA was extracted from P6 mouse retinas and lungs using the RNeasy Plus MiniKit 
(#74134, QIAGEN) according to the manufacturer’s protocol. Samples were quality-controlled and 
quantified using a Nanodrop ND-100 spectrophotometer. Reverse transcription of total RNA was 
performed using a High-Capacity cDNA Reserve Transcription Kit (#4368814, Applied 
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BiosystemsTM). Real-time quantitative PCR was performed using TaqMan Gene Expression 
Assays (Applied Biosystems) and the proprietary TaqMan Gene Expression assay FAM/TAMRA 
primers (Applied Biosystems) for Pdgfb (Mm00440678_m1), Ephb4 (Mm00438750_m1), Efnb2 
(Mm01215897_m1), Nr2f2 (Mm00772789_m1),  Cadh5 (Mm00486938_m1), and Hprt 
(Mm00446968_m1). Pdgfb, Ephb4, Efnb2, and Nr2f2 mRNA expression in retinas was normalized 
to the mRNA of the EC-specific Cdh5 (VE-Cadherin) housekeeping gene.  
 
In vivo rapamycin treatment 
Rapamycin was dissolved at 10 mg/ml in absolute ethanol and used for intraperitoneal injection in 
pups at P1 and P6 at 4 mg/kg. For adult mice, the 10 mg/ml stock of rapamycin in absolute ethanol 
was dissolved further in 5% polyethylene glycol (PEG-400) and 5% Tween-80 in PBS to 0.5 
mg/ml. Mice were dosed with 4 mg rapamycin per kg by intraperitoneal injection every other day 
for a total of 28 days. This dose was based on previous studies using long-term rapamycin 
treatment (45,46). 
 
Statistics 
GraphPad Prism 6 was used for all statistical analysis. Means were compared between two groups 
using the nonparametric Mann–Whitney U test.  All statistical tests and sample size have been 
indicated in the figure legends.  
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Figures 
Figure 1. Mosaic expression of Pik3caH1047R in embryonic mouse mesoderm induces vascular 
malformations. (A) Genetic strategy for mosaic Pik3caH1047R induction in the embryonic 
mesoderm. T-CreERT2 mice were crossed with Pik3caWT/H1047R mice that have a germline Pik3ca 
allele with a conditional H1047R mutation in exon 20. Mosaic recombination in the mesoderm was 
induced by a single intra-peritoneal injection of a low dose of 4-OHT to pregnant mice at E7.5. (B) 
Left, E12.5 T-CreERT2;R26-lacZ mouse embryos from pregnant mice injected with the indicated 
dose of 4-OHT at E7.5 and stained for β-galactosidase (β-gal) activity. Right, Representative 
photographs of P1-P5 MosMes-Pik3caH1047R pups with congenital vascular malformations 
(indicated by arrows in the top panel), born to pregnant mice injected with the indicated 4-OHT 
dose at E7.5. (C) CT-A scans of adult mice four hours after intravenous injection of gold 
nanoparticles. The WT mouse (left) shows normal vascular anatomy, whereas MosMes-
Pik3caH1047R mice display dilatation of the left common iliac vein (arrow) and VM in the urogenital 
area (asterisk) (mouse #1); subcutaneous VM (asterisk) and dilatation of the inferior vena cava 
(arrow) (mouse #2); subcutaneous and urogenital VMs (asterisks) and dilatation of the inferior vena 
cava and portal vein (arrows) (mouse #3). (D) Representative hematoxylin and eosin (H&E)-
stained sections of subcutaneous (left) and deep mesenteric (right) VMs in MosMes-Pik3caH1047R 
mice, showing abnormal, enlarged, and irregular vascular channels, most containing blood and 
organising fibrin thrombi (T), some interposing between skeletal muscle (SM) and other tissue 
structures. No cytological atypia was observed. (P, pancreas). 
 
Figure 2. PIK3CA is mutated in human VMs. (A) Patient 9 showing VMs (PIK3CAH1047L) in the 
lower lip and tongue. (B) Patient 13 with VM (PIK3CAE545K) in the left hand.  
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Figure 3. Endothelial activation of Pik3ca promotes hyperproliferation in ECs and impairs 
pericyte coverage. (A) Schematic of the 4-OHT and EdU administration regime used. (B) 
Representative flat-mounted Pik3caWT and EC-Pik3caH1047R P6 retinas stained with IB4 (red, 
revealing ECs) and antibody to the Erg transcription factor (nuclear marker of ECs; green) and 
labelled with EdU (blue). (C) Quantitative analysis of the retina vessel area (assessed by IB4 
staining), EC numbers (assessed by staining for Erg), and number of proliferating ECs (cells 
positive for both EdU and Erg). Data represent mean  SEM. **p  0.01 (Mann-Whitney U test). 
n=6/genotype. (D) Representative flat-mounted control and EC-Pik3caH1047R P6 retinas stained with 
IB4 and antibody to the Erg transcription factor. (E) Quantification of the radial expansion of 
vasculature in retinas. Data represent mean  SEM. *p < 0.05 (Mann-Whitney U test). 
n=6/genotype. (F) Quantification of the number of sprouts at the vascular front per unit length, and 
the length of sprouts. Data represent mean  SEM. n.s., not significant, p > 0.05 (Mann-Whitney U 
test). n=6/genotype. (G) Flat-mounted Pik3caWT and EC-Pik3caH1047R retinas showing vasculature 
(IB4; red) and pericytes (stained for NG2, a membrane proteoglycan found in pericytes; green). 
Right, higher magnification of highlighted sections. (H) Quantification of pericyte coverage in the 
vasculature of retinas (assessed by % of NG2 staining relative to IB4 staining). Data represent mean 
 SEM. *p < 0.05 (Mann-Whitney U test). n=6/genotype. (I) Pdgfb mRNA expression in EC-
Pik3caH1047R P6 retinas. Data represent mean  SEM. **p < 0.01 (Mann-Whitney U test). 
n=5/genotype. (J) Ephb4, Nr2f2, and Efnb2 mRNA expression in EC-Pik3caH1047R P6 retinas. Data 
represent mean  SEM. n.s., not significant, p > 0.05, *p < 0.05, **p < 0.01 (Mann-Whitney U 
test). n=5/genotype. 
 
 Figure 4. Rapamycin reduces Pik3caH1047R EC hyperproliferation and prevents loss of 
pericyte coverage in postnatal retinas. (A) Schematic of the 4-OHT and rapamycin 
administration regime used for analysis of retinal angiogenesis. (B) Representative flat-mounted P6 
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retinas from vehicle and rapamycin-treated Pik3caWT and EC-Pik3caH1047R pups. Retinas are stained 
with IB4 (red) and antibody to the Erg transcription factor (green) and labeled with EdU (blue). (C) 
Quantitative analysis of the retinal vessel area (assessed by IB4 staining), EC numbers (assessed by 
staining for Erg), and number of proliferating ECs (cells positive for both EdU and Erg). Data 
represent mean  SEM. n.s., not significant, p>0.05, *p < 0.05, **p < 0.01 (Mann-Whitney U test). 
n=6/genotype. (D) Representative flat-mounted P6 retinas from untreated Pik3caWT and EC-
Pik3caH1047R pups and rapamycin-treated EC-Pik3caH1047R pups showing vasculature (IB4; red) and 
pericytes (stained for NG2; green). (E) Quantitative analysis of pericyte coverage in the vascular 
front and plexus of retinas (assessed by % of NG2 staining relative to IB4 staining). Data represent 
mean  SEM. n.s., not significant, p > 0.05, *p < 0.05, **p < 0.01 (Mann-Whitney U test). 
n=6/genotype. 
 
Figure 5. Rapamycin induces regression of Pik3caH1047R-driven VMs in vivo. (A) Measurement 
of the volume of the subcutaneous VM (circled in blue) from CT-A images of mouse #1 (Table 2), 
showing the volume of the VM. H, heart; L, liver; S, spleen. (B) Measurement of the average 
diameter of the inferior vena cava and portal vein from CT-A images of an untreated WT mouse 
and a MosMes-Pik3caH1047R littermate mouse, before and after 2 and 4 weeks of rapamycin 
treatment. IVC, inferior vena cava; PV, portal vein. 
 
Table 1. PIK3CA and TEK mutations in human sporadic VMs  
 
Patient 1 2 3 4 5 6 7 8 9 10 11 12 13 
Age 4 years 20 years 3 years 15 years 3 years 10 years 9 years 15 years 14 years 10 years 20 years 3 years 6 years 
Sex M M M M F F F  F F F F M M 
Location of VM Upper lip 
Sole of 
foot 
Scapular 
area 
Arm, 
chest, 
extensive 
Face Cheek Face Arm 
Tongue, 
lower lip, 
neck 
Tongue, 
lower lip 
Hand Foot Hand 
PIK3CA WT E545K WT WT WT WT WT WT H1047L WT WT WT E545K 
Percent PIK3CA 
mutant allele 
NA 6% NA NA NA NA NA NA 4% NA NA NA 4% 
TEK G1115X WT 
Y897C, 
R918H 
WT WT WT L914F L914F WT L914F WT 
Y897C, 
R918S 
WT 
Percent TEK 
mutant allele 
9% NA 5% NA NA NA 4% 13% NA 5% NA 11% NA 
 
NA: not applicable 
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Table 2. Treatment of MosMes-Pik3caH1047R mice with rapamycin  
 
Mouse # 1 2 3 4 5 6 
Sex m m m f m f 
Phenotype 
Subcutaneous VM at 
right flank, phlebectasia 
of portal vein and 
inferior vena cava  
Subcutaneous VM at left 
flank, phlebectasia of 
portal vein and inferior 
vena cava  
Subcutaneous VM at the 
base of the tail, below 
left hind limb 
Phlebectasia of portal 
vein and inferior vena 
cava. No VM detected 
by CT-A. 
WT 
control 
WT 
control 
Age at starting 
treatment* 
8-week-old 8-week-old 10-week-old 5-week-old 10-week-old 5-week-old 
Duration of 
treatment 
4 weeks 2 weeks 6 weeks 4 weeks 6 weeks 4 weeks 
Outcome 
VM volume reduction: 
32.4% at 2 weeks; 65% 
at 4 weeks.  
Normalization of 
phlebectasias in portal 
vein and inferior vena 
cava. Cessation of 
bleeding of lesion after 1 
week of treatment. 
VM no longer detected 
upon necropsy 4 weeks 
after treatment. 
No volume reduction, 
mouse became ill after 2 
weeks and had to be 
sacrificed in line with 
UK Home Office 
regulations.  
VM volume reduction: 
18.7% at 2 weeks, 28.4% 
at 4 weeks, 37% at 6 
weeks. 
Cessation of rectal 
bleeding immediately 
after treatment 
 
Normalization of 
portal vein and 
inferior vena cava 
phlebectasia 
Overall healthy Overall healthy 
 
* Mice were treated with rapamycin, 4 mg/kg every other day 
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Supplementary Material 
 
Figure S1 
 
 
 
Figure S1. Cre-mediated mosaic recombination in the T-CreERT2 mouse line. (A) 
Schematic representation of the pTcreERT2 transgene used for the generation of the T-
CreERT2 mouse line. (B) Cre-mediated recombination of the Rosa26-lacZ reporter inducing 
β-gal activity. (C) Whole-mount images of E12.5 T-CreERT2;Rosa26-lacZ embryos, stained 
for β-gal after 4-OHT administration at E7.5, E8.5, or E10.5. (D) Same as in (C) but after 
administration of different doses of 4-OHT (5 to 500 µg) at E7.5. 
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Figure S2 
 
 
 
Figure S2. Body weight and organ size of WT and MosMes-Pik3caH1047R mice. Body 
weight over time (A) and organ size at 6 months of age (B) were measured for WT and 
MosMes-Pik3caH1047R mice. Data represent mean  SEM, n=30/genotype for (A), 
n=6/genotype for (B). 
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Figure S3 
 
 
 
Figure S3. Whole-mount endomucin-staining of E9.5 embryos dosed with 170 g 4-OHT 
at E7.5. The MosMes-Pik3caH1047R embryo shows an overall less developed vasculature 
compared to the WT embryo. ov, otic vesicle; YS, yolk sac.  
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Figure S4 
 
 
 
Figure S4. MosMes-Pik3caH1047R mouse with a subcutaneous vascular malformation and 
dilated vein. (A,C) Ultrasound images with color Doppler showing artery (red dashed line) 
and dilated vein (blue dashed line) of a MosMes-Pik3caH1047R mouse. Yellow markers 
indicate the region from which pulsed wave Doppler was acquired. (B,D) Pulsed wave 
Doppler measurement of blood flow demonstrates a high arterial flow velocity wave form 
within the artery (B) and a slow venous flow velocity wave form within the dilated vein (D). 
(E) Power Doppler ultrasound demonstrates slow flow signals in subcutaneous vascular 
malformation. 
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Figure S5 
 
 
 
Figure S5. Immunostaining for lymphatic markers in VMs of MosMes-Pik3caH1047R 
mice. Left, representative image of LYVE-1 immunostaining. Right, representative image of 
PROX-1 immunostaining. 
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Figure S6 
 
 
 
 
Figure S6. Genetic strategy for activating Pik3caH1047R in ECs. Pdgfb-iCreER mice were 
crossed with Pik3caWT/H1047R mice.  
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Figure S7 
 
 
 
Figure S7. Expression of VE-Cadherin in P6 EC-Pik3caH1047R retinas. VE-Cadherin 
mRNA expression was normalized to Hprt. Data represent mean  SEM. *p < 0.05 (Mann-
Whitney U test). n=5/genotype. 
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Figure S8 
 
 
Figure S8. Apoptosis in P9 EC-Pik3caH1047R retinas. (A) Representative flat-mounted 
Pik3caWT and EC-Pik3caH1047R P9 retinas, stained with IB4 (green, revealing ECs) and with 
antibody to cleaved caspase-3 (marker of apoptosis; red). Indicated are apoptotic ECs (orange 
arrows) and non-EC apoptotic cells (white arrowheads). (B) Higher magnification of sections 
highlighted in (A). 
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Figure S9 
 
 
 
Figure S9.  Expression of Pdgfb and arteriovenous markers in EC-Pik3caH1047R lungs. 
(A) Expression of Pdgfb in EC-Pik3caH1047R lungs. Data represent mean  SEM (Mann-
Whitney U test). (B) Expression of Ephb4, Efnb2, and Nr2f2 mRNA in lung lysates of 
Pik3caWT and EC-Pik3caH1047R P6 mice. Data represent mean  SEM. *p < 0.05 (Mann-
Whitney U test). n=5/genotype. 
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Figure S10 
 
 
 
Figure S10. Treatment of MosMes-Pik3caH1047R mice with rapamycin. (A) 3D image 
reconstruction of CT-A of MosMes-Pik3caH1047R mouse #3 before treatment, subcutaneous 
VM highlighted in red. (B) CT-A images of MosMes-Pik3caH1047R mouse #3 upon rapamycin 
treatment showing the volume of the subcutaneous VM (circled in blue). (C) Graph showing 
volumes of VM from MosMes-Pik3caH1047R mice during rapamycin treatment. (D) Graph 
showing average diameter of inferior vena cava and portal vein of MosMes-Pik3caH1047R 
mice during rapamycin treatment. 
 
  
Supplementary Material - Castillo et al. - 11 - 
 
Supplementary Table 1. List of organs and tissues subjected to histological examination.  
The organs were examined by H&E staining in WT and MosMes-Pik3caH1047R mice. 
 
Adrenals Ovaries/oviducts 
Aorta Pancreas 
Brain Parathyroid 
Cecum Prostate 
Cervix Rectum 
Colon Salivary gland 
Duodenum Seminal vesicles 
Epididymis Skeletal muscle 
Esophagus Skin 
Eyes Spleen 
Perigenital fat pad Sternum 
Perirenal fat pad Stomach 
Femur Submandibular lymph nodes 
Heart Testes 
Ileum Thymus 
Jejunum Thyroids 
Kidneys Tongue 
Liver Trachea 
Lungs Urinary bladder 
Mammary glands Uterus/vagina 
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Supplementary Table 2. Percentage of MosMes-Pik3caH1047R mice with VMs after dosing 
with different doses of 4-OHT. 
 
µg 4-OHT 
administered per 
pregnant mouse 
MosMes-Pik3caH1047R mice 
with VMs 
12.5 12.5% 
50 15% 
250 100% 
  
 
Supplementary Table 3. Percentage of live WT and MosMes-Pik3caH1047R offspring after 
different doses of 4-OHT. The expected normal Mendelian distribution is 50% of each 
genotype. 
 
 observed frequency 
µg 4-OHT 
administered per pregnant 
mouse  
WT MosMes-Pik3caH1047R 
12.5 50.0% 50.0% 
50 48.7% 51.3% 
250 61.5% 38.5% 
 
 
